WO2002022175A3 - Method and composition for treating tumors by selective induction of apoptosis - Google Patents

Method and composition for treating tumors by selective induction of apoptosis Download PDF

Info

Publication number
WO2002022175A3
WO2002022175A3 PCT/US2001/028259 US0128259W WO0222175A3 WO 2002022175 A3 WO2002022175 A3 WO 2002022175A3 US 0128259 W US0128259 W US 0128259W WO 0222175 A3 WO0222175 A3 WO 0222175A3
Authority
WO
WIPO (PCT)
Prior art keywords
trail
cells
receptor
express
expression vector
Prior art date
Application number
PCT/US2001/028259
Other languages
French (fr)
Other versions
WO2002022175A2 (en
Inventor
Jian-Yun Dong
James S Norris
Original Assignee
Musc Found For Res Dev
Jian-Yun Dong
James S Norris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev, Jian-Yun Dong, James S Norris filed Critical Musc Found For Res Dev
Priority to EP01970744A priority Critical patent/EP1317288A2/en
Priority to AU2001290720A priority patent/AU2001290720A1/en
Priority to CA002421585A priority patent/CA2421585A1/en
Priority to JP2002526423A priority patent/JP2004526666A/en
Publication of WO2002022175A2 publication Critical patent/WO2002022175A2/en
Publication of WO2002022175A3 publication Critical patent/WO2002022175A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions and methods are provided for inducing death of cancer cells through apotposis mediated by the death ligand, TRAIL. The method comprising: introducing an expression vector into a group of cells comprising cells that express a receptor for TRAIL. The expression vector comprises a polynucleotide sequence encoding TRAIL whose expression is preferably regulated by a conditional promoter in the vector. The cells into which the expression vector is introduced express TRAIL when conditions are suitable to activate the conditional promoter. The expressed TRAIL induces cell death in those cells which express the TRAIL receptor through interaction between TRAIL and the receptor such as DR4 and DR5. The method can be used for treating tumors site-specifically and in a dose-adjustable manner.
PCT/US2001/028259 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis WO2002022175A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01970744A EP1317288A2 (en) 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis
AU2001290720A AU2001290720A1 (en) 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis
CA002421585A CA2421585A1 (en) 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis
JP2002526423A JP2004526666A (en) 2000-09-11 2001-09-10 Compositions and methods for treating tumors by selective induction of apoptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65877900A 2000-09-11 2000-09-11
US09/658,779 2000-09-11

Publications (2)

Publication Number Publication Date
WO2002022175A2 WO2002022175A2 (en) 2002-03-21
WO2002022175A3 true WO2002022175A3 (en) 2002-08-08

Family

ID=24642656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/028259 WO2002022175A2 (en) 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis

Country Status (6)

Country Link
EP (1) EP1317288A2 (en)
JP (1) JP2004526666A (en)
CN (1) CN1744919A (en)
AU (1) AU2001290720A1 (en)
CA (1) CA2421585A1 (en)
WO (1) WO2002022175A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621550A1 (en) * 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
CA2585775C (en) 2004-10-29 2013-10-01 Musc Foundation For Research Development Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
WO2006050265A2 (en) 2004-10-29 2006-05-11 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
CN101144081B (en) * 2006-09-14 2011-06-22 复旦大学 Nucleic acid molecule TRAIL and application in preparation of anti-tumour pharmaceutical
CA2742866C (en) 2008-11-06 2017-10-24 Musc Foundation For Research Development Lysosomotropic inhibitors of acid ceramidase
MX2012005340A (en) * 2009-11-05 2012-12-05 Proyecto Biomedicina Cima Sl Regulated expression systems.
JP5551793B2 (en) * 2010-04-01 2014-07-16 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー TRAIL sensitivity-enhancing composition containing an inhibitor for suppressing the expression or activity of TIP41, a TRAIL sensitizer target gene
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014205516A1 (en) 2013-06-25 2014-12-31 The Walter And Eliza Hall Institute Of Medical Research Method of treating intracellular infection
CN105126120B (en) * 2015-08-24 2018-12-21 浙江大学 Long non-coding RNA H19 and cancer platinum-based chemotherapy Drug-resistant correlation
CN111110867A (en) * 2016-06-03 2020-05-08 国家农艺研究院 Controlled expression of nucleic acids encoding pro-apoptotic proteins
CA3057680A1 (en) * 2017-03-24 2018-09-27 Ohio State Innovation Foundation Novel recombinant adeno-associated viral vectors restricting off-target transduction in liver and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079495A1 (en) * 2000-04-12 2001-10-25 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/apo-2 ligand gene transfer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079495A1 (en) * 2000-04-12 2001-10-25 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/apo-2 ligand gene transfer

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
CELL DEATH AND DIFFERENTIATION, vol. 6, no. 2, February 1999 (1999-02-01), pages 175 - 182, ISSN: 1350-9047 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1998 (1998-04-01), LARREGINA A T ET AL: "FasL induces Fas/Apo1-mediated apoptosis in human embyronic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors.", XP002196492, Database accession no. PREV199800256744 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 1999 (1999-02-01), HEDLUND TAMMY E ET AL: "Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells.", XP002196491, Database accession no. PREV199900167152 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 2000 (2000-05-01), RUBINCHIK S ET AL: "Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system.", XP002196490, Database accession no. PREV200000281947 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; WEI X.-C. ET AL: "Killing effect of TNF - related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87.", XP002196489, retrieved from STN Database accession no. 2001300249 *
GENE THERAPY, vol. 5, no. 4, April 1998 (1998-04-01), pages 563 - 568, ISSN: 0969-7128 *
GENE THERAPY, vol. 7, no. 10, May 2000 (2000-05-01), pages 875 - 885, ISSN: 0969-7128 *
GRIFFITH T S ET AL: "Adenoviral-mediated gene transfer of TRAIL induces tumor cell apoptosis", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A1003, XP002176065, ISSN: 0892-6638 *
GRIFFITH T S ET AL: "ADENOVIRAL-MEDIATED TRANSFER OF THE TNF-RELATED APOPTOSIS-INDUCING LIGAND/APO-2 LIGAND GENE INDUCES TUMOR CELL APOPTOSIS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 165, 1 September 2000 (2000-09-01), pages 2886 - 2894, XP002176066, ISSN: 0022-1767 *
GURA ET AL: "HOW TRAIL KILLS CANCER CELLS, BUT NOT NORMAL CELLS", SCIENCE, vol. 77, 1997, pages 768, XP002196487 *
KAGAWA SHUNSUKE ET AL: "Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.", CANCER RESEARCH, vol. 61, no. 8, 15 April 2001 (2001-04-15), pages 3330 - 3338, XP002196485, ISSN: 0008-5472 *
MANO TOSHIAKI ET AL: "Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions.", HUMAN GENE THERAPY, vol. 11, no. 12, 10 August 2000 (2000-08-10), pages 1625 - 1635, XP002196486, ISSN: 1043-0342 *
MORELLI A E ET AL: "NEURONAL AND GLIAL CELL TYPE-SPECIFIC PROMOTERS WITHIN ADENOVIRUS RECONBINANTS RESTRICT THE EXPRESSION OF THE APOPTOSIS-INDUCING MOLECULE FAS LIGAND TO PREDETERMINED BRAIN CELL TYPES, AND ABOLISH PERIPHERAL LIVER TOXICITY", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 80, 1999, pages 571 - 583, XP002936209, ISSN: 0022-1317 *
ROTH W ET AL: "TODESLIGANDEN/TODESREZEPTOREN ALS ANGRIFFSPUNKT DER SOMATISCHEN GENTHERAPIE MALIGNER GLOME", NEUROFORUM, SPEKTRUM AKAD. VERLAG, HEIDELBERG, DE, vol. 5, no. 3, 1999, pages 87 - 92, XP001016223, ISSN: 0947-0875 *
SGAGIAS MAGDALENE K ET AL: "Induction of apoptosis by adenovirus-mediated over-expression of BRCA1 in T47D human breast cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 537, XP002196488, ISSN: 0197-016X *
WORLD JOURNAL OF GASTROENTEROLOGY, (2001) 7/4 (559-562). *

Also Published As

Publication number Publication date
AU2001290720A1 (en) 2002-03-26
WO2002022175A2 (en) 2002-03-21
CN1744919A (en) 2006-03-08
CA2421585A1 (en) 2002-03-21
JP2004526666A (en) 2004-09-02
EP1317288A2 (en) 2003-06-11

Similar Documents

Publication Publication Date Title
WO2002022175A3 (en) Method and composition for treating tumors by selective induction of apoptosis
IL193886A0 (en) Antibodies that bind to ldcam sequences
HK1034287A1 (en) Recombinational cloning using nucleic acids havingrecombination sites
IL138937A0 (en) Lineage specific cells, progenitor cells and methods for generating the same
GB9308271D0 (en) Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
AU7013401A (en) Methods for enhancing antibody-induced cell lysis and treating cancer
MXPA02009843A (en) T2r taste receptors and genes encoding same.
NO20001684L (en) Methods and compositions to induce tumor-specific cytotoxicity
HK1070077A1 (en) Chimeric tnf ligands
ATE148468T1 (en) NEW ICE CORE-FORMING MICROORGANISMS
ZA985781B (en) Methods for using compositions containing dichlorophenyl imidazoldioxolan to treat seborrheic dermatitis, dandruff, psoriasis, and acne, and compositions thereof.
MX9606559A (en) Cancer therapy using lymphotoxin.
Kang et al. The tectonic evolution from the archean to triassic in the north central gyeonggi massif (hongcheon-chuncheon areas) in the Korean peninsula, and its application to the tectonic evolution of the North China craton
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
Zhai et al. SHRIMP Zircon U-Pb dating of the Hetai gold deposit in Western Guangdong, China and geological implications
WO2001025398A3 (en) Process for inducing functional tolerance to gene transfer products
Duggal et al. Promising Preliminary Activity of Optimized Affinity, CD38 CAR NK Cells Generated Using a Non-Viral Engineering Approach in Gene Edited Cord Blood Derived NK Cells for the Treatment of Multiple Myeloma
Lee et al. Comment on" The effect of kaolin particles on the behavior of nitrifying activated sludge units"
Liu et al. Experimental Study on the Leaching of Gold from Greenstone1
Zelenkova et al. The role of electron detachment in collisions with neutral molecules in the transformation processes of negative ions
Poelt Die Entstehung einer Strauchflechte aus einem Formenkreis krustiger Verwandter 1) 1) Herrn Prof. Dr. H. Meusel zum 80. Geburtstag gewidmet.
Csutor Effect of the Feed Properties on the Quality of Pig Iron
Liu Gold Deposits in Precambrian Banded Iron-Formations—A Case Study of the Dongfengshan Gold Deposit1
Samus et al. VizieR Online Data Catalog: CCD BVI photometry in NGC 5927 (Samus+, 1996)
Krylov et al. Quaternary paleoceanography of the Amerasian Basin of the Arctic Ocean, as reflected in sedimentary record from the Mendeleev Rise

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2421585

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001970744

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002526423

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001290720

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018173152

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001970744

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001970744

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)